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Occupation of membrane receptors can evoke calcium signals by causing depolarisation and activating voltage-operated calcium channels, by trig- 
gering internal release, or by stimulating calcium influx processes not gated by membrane potential, receptor-mediated calcium entry, RCME. This 
brief review considers different possible coupling mechanisms and the proposal that entry can occur from external medium to intracellular store, 
by-passing the cytosol. and regulated by the state of filling of the store. Recent studies using MnZ+ as a probe for RCME are outlined. as are 
some new electrophysiologic measurements with human platelets and investigations of a novel blocker of RMCE, SK&F 96365. 
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1. INTRODUCTION 
With the central importance of cell calcium in cell 
signalling, it is not surprising that diverse mechanisms 
for Ca2+ mobilisation have evolved. We can recognise 
3 main classes; Ca*+ discharge from internal stores, 
voltage-gated Ca2+ channels and receptor-mediated 
processes that exploit Ca*+ entry from the external 
medium. An operational definition of receptor- 
mediated Ca2+ entry, RMCE (see [l]) is ‘an influx of 
Ca*+ consequent on receptor occupation and not 
dependent on depolarisation that generates a biological- 
ly significant increase in [Ca*+]i’. We thus include 
significant Ca2+ entry through non-specific cation 
channels as well as entry via Ca2+ selective channels. 
Various mechanisms for RMCE are shown diagram- 
matically in Fig. 1. RMCE may occur via mechanisms 
tightly coupled to the ligand binding site, analogous to 
the nicotinic receptor/channel complex (l), coupled to 
receptors via G-proteins (2); these may reasonably be 
termed receptor-operated calcium channels (ROCC’s). 
More indirect activation could occur via diffusible in- 
tracellular second messengers (3). There is also 
postulated Ca*+ entry that is linked to the state of filling 
of the internal dischargeable Ca2+ pool, such that 
depletion of the pool promotes either entry into the 
pool by-passing the bulk of the cytosol (4a), or an in- 
creased CaZf permeability of the plasma membrane 
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allowing additional Ca2 influx into the cytosol (4b), see 
e.g. [l-3]. Physiologically, the Ca2+ pool is discharged 
following receptor occupation and one can therefore 
consider this indirect type of mechanism under the 
general heading of RMCE. 
We know and understand much less about the func- 
tion and mechanism of RMCE than about voltage- 
gated Ca2+ entry. Among the reasons for this difference 
are: (i) the lack of potent specific ligands for RMCE; (ii) 
the difficulty of reliably detecting and measuring cur- 
rents associated with RMCE at whole cell or single 
channel level; (iii) the close temporal and functional 
association of RMCE with internal Ca2+ release; and 
(iv) the apparent diversity of mechanisms and the possi- 
ble existence of more than one type of RMCE in many 
cells. 
Possible functions of RMCE include: localised Ca*+ 
signalling, rapid signalling in non-excitable cells, 
maintenance of Ca2+ signals, refilling of discharged in- 
ternal Ca2+ pools, and control [Ca2+]i spiking, see e.g. 
[1,4]. It is worth pointing out that in many cells the in- 
itial response, and the main source of [Ca2+]i spikes, is 
the internal store. 
Thus pharmacologic modulation of RMCE could 
limit pathologic sustained responses while leaving intact 
the major component of early phase rapid Ca*+ 
signalling. 
This paper will note some recent developments in the 
field, focusing on: studies of RMCE with fluorescent 
indicator dyes; electrophysiologic data; and some 
results obtained with novel compounds that can inhibit 
RMCE in a variety of cells. 
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Fig. I, Various mechanisms of RMCE. 1, receptor-channel complex; 
2, receptor coupled to channel via a G-protein; 3, second messenger 
operated channel; 4a, entry into store regulated by store C‘a’*; 4b, en- 
try to cytosol regulated by store Ca”. 
2. STUDIES WITH FLUORESCENT INDICATORS 
In many non-excitable cells, agonist-evoked Ca’+ 
signals are often transient in media lacking external 
Ca2+, and are somewhat larger with a maintained 
plateau (or, if single cells are studied, persistent spiking) 
in normal external Ca2+. The most likely explanation is 
that the external Ca2+ sustains an RMCE. Yet one can- 
not always exclude a role for external Ca’+ in the effec- 
tive coupling of receptor to Ca2’ discharge, and the 
relative contribution and timing of discharge and entry 
can be hard to distinguish. ‘5Ca2+ influx studies do in- 
dicate increased Ca2+ entry following stimulation in 
several cell types; and some recent studies have effec- 
tively combined 45Ca uptake measurements with 
monitoring of fura- fluorescence [4,5]. 
We introduced Mn2+ as an additional tool for this 
type of study [6]. Quin2, fura- and indo-l have high 
affinities for Mn2’, and upon binding Mn2+ the dye 
fluorescence is quenched. Agonist-stimulated quench- 
ing of the signal from quin2-loaded platelets in the 
presence of extracellular Mn2+ provided the first direct 
evidence for stimulated influx of extracellular divalent 
cations into the cytosol of dye-loaded cells [6]. Inter- 
pretation of the results using quin2 were complicated 
because the quench due to Mn2+ entering the cytosol 
was superimposed on the rise in fluorescence due to the 
agonist-stimulated discharge of internal Ca2+ stores. A 
recent development of this approach using dual 
wavelength excitation with fura- substantially over- 
comes this problem 171. One of the excitation 
wavelengths is chosen to be 340 nm where Ca2+ in- 
creases the signal, and the other is chosen at the 
isostilbic wavelength, 360 nm, where the fluorescence 
of fura- is insensitive to [Ca’+]i. Mn” suppresses the 
fluorescence at all wavelengths and thus the 360 nm ex- 
citation signal provides a monitor for Mn”+ influx un- 
contaminated by any simultaneous changes in [Ca’+]i. 
Our group has used the Mn’+ approach to extend the 
original studies with platelets and to examine agonist- 
evoked Mn2+ entry in human neutrophils and en- 
dothelial cells [7,8]. In these cells Mn2+ appears to serve 
as an effective surrogate for Ca2+ entry, at least 
through some pathways; interestingly a detailed 
analysis of thrombin-evoked Mn’+ entry in platelets 
gave a hint of one type of Ca2+ entry non-permeant to 
Mn2+ [9]. Also Merritt and Hallam [IO] could not 
detect Mn” entry into carbachol-stimulated parotid 
cells under conditions in which RMCE was strongly in- 
dicated by other data. An important finding, par- 
ticularly from the work on endothelial cells, is that 
Mn2+ entry appears to be regulated at least in part by 
the state of filling of the dischargeable Cali stores 
rather than actual occupancy of receptors. 
This has been examined in some detail by brief ap- 
plication of histamine to superfused, single 
fura-2-loaded human umbilical vein endothelial cells 
followed by application of Mn2+ to assess the rate of 
Mn2+ entry. The initial rate of entry showed a striking 
inverse relation to the state of fullness of the Ca2+ store 
[I I] consistent with mechanism 4a or 4b in Fig. 1. 
We have also studied the time-course of agonist- 
evoked fura- signals in several cell types using both 
standard cuvette fluorescence, and stopped-flow 
measurements for rapid sub-second kinetics. Internal 
Ca2+ release evoked by maximal agonist concentration 
occurs with the delay of approx. 60 ms in parotid cells 
[ 121, 200-300 ms in platelets [ 131, and 500-800 ms in 
neutrophils [14] and endothelial cells (R. Jacob, per- 
sonal communication). In almost all instances we found 
that Ca’+, or Mn’+, entry occurred after or at least no 
sooner than the evoked internal Ca’+ release. These 
temporal relations are consistent with mechanisms 4a 
and 4b (store-control of entry) or mechanism 3 if the 
second messenger mediation of entry is no faster than 
that for internal release. However, in one instance, with 
ADP stimulation of human platelets, we find a very ear- 
ly phase of Ca2+ or Mn2+ entry with a delay of less than 
20 ms [9,13] strongly suggesting that mechanism 1 or 2 
of Fig. 1 applies to these particular purinergic receptors 
and the associated Ca2+ entry. 
3. ELECTROPHYSIOLOGIC STUDIES 
Perhaps the most widely recognised ROCC’s are 
those detected actually in excitable cells; namely, ATP- 
activated channels in arterial smooth muscle where both 
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whole cell Ca’+ currents and single channels were 
recorded [ 151, and the NMDA type of glutamate recep- 
tor channel in central neurones (e.g. [16]). Very recently 
evidence for receptor-operated channels that are cation 
permeable and can carry a Ca*+ (or Ba*+) current have 
been found by patch-clamp studies of non-excitable 
cells e.g. in BALB 3T3 cultured cells stimulated by 
insulin-like growth factor [17], and in our own cell- 
attached patch-clamp studies of ADP-activated chan- 
nels in intact human platelets [18]. ADP applied in the 
pipette, but not via the bath, induces single channels; 
this finding implies a direct or tight coupling rather than 
coupling via diffusible second messengers. The chan- 
nels are permeable to Na+ and Ba’+, but not to Cl-, 
with a conductance of approx. 11 pS at the resting 
potential. They are blocked by Ni2+, as is the ADP- 
evoked Ca*+ or Mn2+ entry detected by fura-2. Thus we 
suspect that ADP acts via ROCC’s to evoke its very 
rapid responses in human platelets. 
Evidence is emerging for second messenger activated 
Ca channels, SMOCCs [ 191, in a variety of cells and ex- 
perimental paradigms. Von Tscharner et al. [20] 
reported data suggesting that a Ca2+ permeable channel 
was activated by elevated [Ca*‘]i in human neutrophils. 
If this mechanism is present it is not probably the main 
pathway since one can find experimental conditions 
where agonists evoke Ca*+ or Mn2+ entry at basal 
[Ca’+]i (e.g. [7]). Inositol trisphosphate has been pro- 
posed as an activator of Ca*+ entry from work with ex- 
cised inside-out patches of lymphocyte membranes, and 
from whole cell recordings of mast cells with inositol 
trisphosphate applied via the pipette [21,22]. In 
lacrimal cells studied with internally perfused patch- 
pipettes the results point to a cooperative action of in- 
ositol trisphosphate and inositol tetrakisphosphate in 
activating Ca2+ entry [23]. In none of these studies does 
the evidence conclusively distinguish between mecha- 
nism 3, which one might at first sight assume to be 
operating, and either mechanism 4a or 4b; these latter 
mechanisms could apply since the opening of the in- 
ositol trisphosphate-activated channel in the internal 
store could result in an inward current by a conductive 
pathway across the plasma membrane, either through 
the store and via the InsP3 channel or across the plasma 
membrane. 
This brief account is by no means comprehensive, but 
serves to introduce this complex topic and point to some 
of the proposals for the different routes of RMCE, and 
different intracellular controls on calcium flux. 
4. BLOCKING RECEPTOR-MEDIATED CALCIUM 
ENTRY 
Two general classes of agents have been employed to 
block voltage-dependent Ca*+ entry. A diverse range of 
organic compounds has been identified of which 
nifedipine, diltiazem and verapamil are leading ex- 
amples. They were identified from their potent phar- 
macological actions, typically relaxation of smooth 
muscle, and subsequently identified as potent and 
rather specific ‘antagonists’ of L-type VOC’s [24]. 
Other compounds including certain toxins are now 
emerging as somewhat specific for other classes of 
VOC’s (e.g. [25]). Also known to block Ca*+ currents 
through VOC’s are a range of divalent and trivalent ca- 
tions including Ni2+, Co*+, Cd*+, and La3’ (e.g. [26]). 
Moreover the apparent affinities of these cations in 
blocking different classes of VOC’s are different so that 
they may be helpful not only in inhibiting Ca*+ cur- 
rents, but in distinguishing the type of VOC through 
which the current is passing [25]. 
These inorganic ions also appear to block RMCE. 
Different investigators have chosen particular inorganic 
cations for this purpose, usually Ni*+, Cd*+ or La3’. 
We have most frequently used Ni*’ which has an ICsO 
of about 1.5 mM in inhibiting the Ca*’ entry compo- 
nent stimulated by various ligands in neutrophils [7], 
and a similar apparent potency in human platelets 
(Leigh and Rink, unpublished results), and human en- 
dothelial cells [8]. Interestingly Ni2+ also blocks RMCE 
in parotid cells [9]. Ni*+ is equally effective in blocking 
Mn2+ entry as it is with Ca2+ entry [6,7]. In human 
platelets, stimulated by ADP, Cd*+ appears to be some 
5 times more potent than NiZf and for that reason may 
be preferred (Leigh and Rink, unpublished observa- 
tions). Co’+ blocks Ca2+ in platelets but also permeates 
slowly, and is thus less useful than Ni*+ which does not 
measurably permeate. 
These inorganic RMCE blockers can be valuable for 
in vitro experiments, complementing the approach of 
removing Ca2+ from the external medium. For exam- 
ple, Ca*+-free solutions are known to have quite diverse 
effects on membrane function and this may be par- 
ticularly pronounced when chelators such as EGTA are 
used to reduce residual Ca*+ contamination. In the 
analysis of sub-second kinetics of [Ca’+]i signals in 
human platelets we found it valuable to show that in ex- 
periments in which Ni*+ blocked Ca2+ entry the results 
were closely similar to those seen with EGTA present; 
this result suggested that EGTA treatment had not pro- 
duced artifactual changes in the observed response [ 131. 
However, these inorganic ions are not specific for 
RMCE and have very limited utility in any in vivo ex- 
periments. 
At sufficiently high concentrations, usually l-3 
orders of magnitude higher than those required to in- 
hibit voltage-dependent Ca2+ entry, the organic ‘Ca’+ 
antagonists’, do reduce, sometimes substantially, 
RMCE (e.g. [27]). In our hands, the dihydropyridines 
are considerably more effective than diltiazem in 
human platelets with I&s in the range lo-20 PM. 
There appears to be some selectivity for RMCE in that 
agonist-evoked internal Ca*+ discharge is less affected. 
Whether these agents are acting at a site similar to that 
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by which to influence VOCs remains to be determined. ple a fast and massive influx of activator Ca’+ through 
It should also be noted that at this concentration these the plasma membrane may be the ideal mechanism to 
Ca antagonists can have other effects on cellular pro- achieve rapid response of blood platelets in blood 
cesses including other types of ion channels, agonist vessels on exposure to ADP. In contrast, it may make 
receptors and intracellular Ca’+ target proteins. Clearly a great deal of sense for small refilling fluxes to be trig- 
the absence of specific and potent ligands of RMCE gered during chronic low stimulation of endothelial 
processes is a serious detriment to progress in working cells and hepatocytes. It is worth pointing out that the 
out their functional role and the structural basis, and we Ca2* flux via RMCE may be very small during prolong- 
have looked for new classes of compounds which might ed stimulation, l-3 orders of magnitude less than the 
act in this way. (brief) influx obtainable via VOC’s in a Ca’+ spike. 
One compound we have studied, SK&F 96365, l-p- 
[3-(p-methoxyphenyl)-propyloxy]-p-methoxyphenetyl- 
lH-imidazole hydrochloride, is able essentially to 
abolish RMCE, and agonist-evoked Mn2+ entry, in a 
range of non-excitable cells. The ICso is usually around 
10 PM, with little or no effect on agonist-evoked inter- 
nal release at 30-lOOhM [28]. This compound produces 
a blockade of RMCE or Mn2+ entry evoked by all 
agonists tested in human platelets, human neutrophils 
and human umbilical vein endothelial cells. For exam- 
ple, 1OpM SK&F 96365 greatly reduces the Mn2+ influx 
normally evoked by F-Met-Leu-Phe in fura-2-loaded 
neutrophils without significantly altering the signal at- 
tributable to discharge of internal stores. Interestingly 
this compound appears to be less effective in blocking 
Ca’+ entry through the ATP-linked channel in smooth 
muscle cells; 20,&I SK&F 96365 had no discernible ef- 
fect in this system. The selectivity that this compound 
displays for RMCE over internal release does not ap- 
parently translate to a selectivity between RMCE and 
voltage gated Ca2+ entry at least in two systems tested. 
SK&F 96365 inhibited K’-induced [Ca’+]i elevation in 
GH3 cells with an lC50 in the range 1OpM and this con- 
centration produced a marked reduction in the Ba2+ 
current attributable to L-type VOCs in patch-clamped 
smooth muscle cells. 
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